No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ZVRA241220P8000
- 0.05
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume45 Open Interest8.00Strike Price0.00Turnover3033.67%IV3.17%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-10DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1747Delta0.4983Gamma164.20Leverage Ratio-45.0906Theta0.0000Rho-28.69Eff Leverage0.0000Vega
Intraday
- 5D
- Daily
News
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long
Top Picks for 2025 in Healthcare, Consumer, Tech, Industrials, Energy and More
Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Zevra Therapeutics Restructures to Focus on Rare Diseases
Express News | Zevra Therapeutics Inc - Christal M.m. Mickle, Chief Development Officer, and Sven Guenther, Ph.d., Chief Scientific Officer, to Depart Co
Express News | Zevra Therapeutics Inc - Zevra Has Discontinued Its in-House Drug Discovery Activities